Gilead Sciences
GILD BiotechAntiviral specialist with dominant HIV franchise (Biktarvy, Descovy) and hepatitis C cures. Expanding into oncology through acquisitions.
Gilead Sciences at a Glance
- Leading 27 drug targets across portfolio
- Fast trial execution (23 months median completion)
Upcoming FDA Decisions
Full Calendar →Key Drugs
Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.
Recent FDA Approvals
New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.
Therapeutic Areas
Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.
Top Competitors
Companies with the most overlap in therapeutic areas and drug targets. Based on approved drugs and pipeline focus.
Pipeline Snapshot
Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Trial Catalysts
- • Infectious Disease pipeline focus
- • 8 Phase 3 readouts tracked
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 115/161 completed
- • Speed: 23 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (17)
Company Info
- First Approval
- 1996-06-26
- Latest
- 2026-03-12
- Applications
- 36
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges